A 58‐year‐old female with an 18‐year history of limited cutaneous systemic sclerosis presents with severe pain and ulceration affecting the tips of her fingers. On examination, there was evidence of auto‐amputation of some of her distal phalanges and ulceration of the overlying skin. What’s the diagnosis?
The latest research on gastric antral vascular ectasia (GAVE) in systemic sclerosis and serositis in antisynthetase syndrome (ASS) sheds new light on these little-understood diseases.
The clinical phenotype of melanoma differentiation associated protein 5 (MDA-5) dermatomyositis represents an overlap of a severe form of vasculopathy and rapidly progressive ILD.
Chronic and severe digital ischemia and nailfold capillaraoscopy help differentiate secondary from primary Raynaud phenomenon. Secondary Raynaud should prompt an investigation for autoimmune rheumatic disease.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
To clarify conflicting reports on the incidence of breast cancer in SSc, a research team studies the development of breast cancer in SSc patients and compares them with a nonscleroderma cohort of breast cancer patients.
These nine slides depict calcinosis, including the case of a 29-year-old female whose dystrophic calcinosis progressed relentlessly, ultimately covering her entire body like an exoskeleton.
Many patients with idiopathic recurrent pericarditis require prolonged glucocorticoids (GC), but GCs increase morbidity. Cleveland Clinic is studying alternative agents, including azathioprine, for these patients.
Results of a small retrospective study on the use of immunosuppressive therapy show promise for preventing recurrent bleeding episodes in GAVE.
Does annual screening for pulmonary hypertension make sense in patients with anti-PM-Scl antibody? That’s one question raised by a new retrospective analysis of pulmonary manifestations of the antibody.
Skin thickening figures prominently in almost all cases of systemic sclerosis. Effective treatments are scarce, but not for lack of investigations of new options. Here’s a rundown of the most promising.